Shutting off methadone. Costs and benefits. 1981

W H McGlothlin, and M D Anglin

We report the findings of a two-year follow-up of the 99 methadone clients enrolled in the Bakersfield, Calif, clinic when it was closed in September 1976. Because of the remote location, only 11 transferred to another clinic. A sample of 88 were selected from a continuing program for comparison. Ninety-five percent of the combined samples were interviewed. Fifty-four percent of the terminated clients became readdicted to heroin, and the arrest and incarceration rates were approximately double that for the comparison sample. The simultaneous initiation of a special police narcotic task force may have contributed to the arrest rate and limited the percent of time addicted. The net economic costs subsequent to discharge were slightly less than that for the comparison group; however, when the benefits resulting from new admissions are considered, the clinic closing represented an economic loss in addition to the detrimental effects experienced by the clients.

UI MeSH Term Description Entries
D008297 Male Males
D008691 Methadone A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3) Amidone,Biodone,Dolophine,Metadol,Metasedin,Methaddict,Methadone Hydrochloride,Methadose,Methex,Phenadone,Phymet,Physeptone,Pinadone,Symoron,Hydrochloride, Methadone
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D003362 Cost-Benefit Analysis A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. In contrast a cost effectiveness in general compares cost with qualitative outcomes. Cost and Benefit,Cost-Benefit Data,Benefits and Costs,Cost Benefit,Cost Benefit Analysis,Cost-Utility Analysis,Costs and Benefits,Economic Evaluation,Marginal Analysis,Analyses, Cost Benefit,Analysis, Cost Benefit,Analysis, Cost-Benefit,Analysis, Cost-Utility,Analysis, Marginal,Benefit and Cost,Cost Benefit Analyses,Cost Benefit Data,Cost Utility Analysis,Cost-Benefit Analyses,Cost-Utility Analyses,Data, Cost-Benefit,Economic Evaluations,Evaluation, Economic,Marginal Analyses
D003415 Crime A violation of the criminal law, i.e., a breach of the conduct code specifically sanctioned by the state, which through its administrative agencies prosecutes offenders and imposes and administers punishments. The concept includes unacceptable actions whether prosecuted or going unpunished. Kidnapping,Poaching,Crimes,Kidnappings
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006556 Heroin Dependence Strong dependence or addiction, both physiological and emotional, upon HEROIN. Heroin Abuse,Heroin Addiction,Heroin Smoking,Abuse, Heroin,Addiction, Heroin,Dependence, Heroin,Heroin Smokings,Smoking, Heroin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

W H McGlothlin, and M D Anglin
January 1989, Addictive behaviors,
W H McGlothlin, and M D Anglin
October 1996, PharmacoEconomics,
W H McGlothlin, and M D Anglin
June 2003, The Journal of clinical investigation,
W H McGlothlin, and M D Anglin
November 2005, Health economics,
W H McGlothlin, and M D Anglin
January 2018, Biomolecules & therapeutics,
W H McGlothlin, and M D Anglin
November 2001, Clinical genetics,
W H McGlothlin, and M D Anglin
January 1993, The American journal of drug and alcohol abuse,
W H McGlothlin, and M D Anglin
January 1992, American journal of diseases of children (1960),
W H McGlothlin, and M D Anglin
April 2016, Hepatology (Baltimore, Md.),
W H McGlothlin, and M D Anglin
January 2022, Oncology letters,
Copied contents to your clipboard!